Reviewing Monoclonal Antibody Adverse Effects Monoclonal antibody therapy has revolutionized the management of oncologic and immunologic diseases. However, they also are associated with adverse effects. In a comprehensive review of adverse effects of 110 agents that have been approved by FDA and/or by the European Medicines Agency, the authors identified both immune- and nonimmune-mediated adverse reactions associated with these drugs. Read more.
|
Clinic-Based Real-World Experience With IV Ketamine for Depression
While esketamine, the S-isomer of ketamine, is approved by the FDA for treatment-resistant depression and major depressive disorder with suicidality, IV ketamine—a mixture of R- and S-isomers—remains off-label for this indication. In a position paper, the American College of Clinical Pharmacy expressed concern about the inherent unfavorable risk-benefit profile of off-label ketamine. Read more.
|